research use only
Cat.No.S3690
| Molecular Weight | 195.69 | Formula | C11H13N.HCl |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 306-07-0 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Pargylamine hydrochloride | Smiles | CN(CC#C)CC1=CC=CC=C1.Cl | ||
|
In vitro |
DMSO
: 39 mg/mL
(199.29 mM)
Water : 39 mg/mL Ethanol : 39 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
MAO-B
(Cell-free assay) 0.5 μM(Ki)
MAO-A
(Cell-free assay) 13 μM(Ki)
|
|---|---|
| In vitro |
Pargyline, an MAO inhibitor, prevents the activity of lysine-specific demethylase 1 (LSD1) and is excessively expressed in breast cancer. The proliferation of cells exposed to pargyline decreases in a dose- and time-dependent manner. The treatment of 2 mM pargyline exhibits an increase of the cell proportion at the G1 phase, while the major decrease of the cell proportion is at the S phase. Pargyline induces an increase in the cleaved PARP expression.
|
| In vivo |
Chronic treatment (14 days) with pargyline (10 mg/kg) markedly down-regulate the density of NAIBS (non-adrenoceptor idazoxan binding sites) in the rat brain.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.